Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.

Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferriere V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156. [Epub ahead of print]

PMID:
30649045
2.

Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.

Kronfli N, Nitulescu R, Cox J, Moodie EE, Wong A, Cooper C, Gill J, Walmsley S, Martel-Laferrière V, Hull MW, Klein MB; Canadian Co-Infection Cohort Study.

J Int AIDS Soc. 2018 Nov;21(11):e25197. doi: 10.1002/jia2.25197.

3.

New Canadian guideline provides evidence-based approach to non-occupational HIV prophylaxis.

O'Donnell S, Tan DHS, Hull MW.

CJEM. 2019 Jan;21(1):21-25. doi: 10.1017/cem.2018.462. Epub 2018 Nov 20.

PMID:
30457087
4.

Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey.

Wang S, Kortenaar JL, Hull MW, Arbess G, Owen JR, Tan DH.

Patient Prefer Adherence. 2018 Oct 16;12:2197-2204. doi: 10.2147/PPA.S178403. eCollection 2018.

5.

Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals.

Butt ZA, Shrestha N, Gesink D, Murti M, Buxton JA, Gilbert M, Balshaw RF, Wong S, Kuo M, Wong J, Yu A, Alvarez M, Samji H, Roth D, Consolacion T, Hull MW, Ogilvie G, Tyndall MW, Krajden M, Janjua NZ.

Clin Epidemiol. 2018 Aug 31;10:1127-1145. doi: 10.2147/CLEP.S173449. eCollection 2018.

6.

The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study.

Ma H, Villalobos CF, St-Jean M, Eyawo O, Lavergne MR, Ti L, Hull MW, Yip B, Wu L, Hogg RS, Barrios R, Shoveller JA, Montaner JSG, Lima VD.

BMC Health Serv Res. 2018 May 2;18(1):319. doi: 10.1186/s12913-018-3119-5.

7.

Trends in discharges from the HIV/AIDS ward at a tertiary Canadian Hospital from 2005 to 2014.

Jaworsky D, Phillips P, Cui Z, Chau W, Colley G, Dutta R, Yip B, Kremer H, Eyawo O, Montaner JS, Hull MW.

AIDS Care. 2018 Sep;30(9):1099-1106. doi: 10.1080/09540121.2018.1434121. Epub 2018 Feb 4.

PMID:
29397766
8.

Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012-2016.

Mosley T, Khaketla M, Armstrong HL, Cui Z, Sereda P, Lachowsky NJ, Hull MW, Olarewaju G, Jollimore J, Edward J, Montaner JSG, Hogg RS, Roth EA, Moore DM.

AIDS Behav. 2018 Nov;22(11):3550-3565. doi: 10.1007/s10461-018-2026-4.

PMID:
29344740
9.

Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada.

Eyawo O, Hull MW, Salters K, Samji H, Cescon A, Sereda P, Lima VD, Nosyk B, Whitehurst DGT, Lear SA, Montaner JSG, Hogg RS; Comparative Outcomes And Service Utilization Trends (COAST) Study.

BMJ Open. 2018 Jan 13;8(1):e019115. doi: 10.1136/bmjopen-2017-019115.

10.

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.

Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P, Thomas R, Kille J, Baril JG, Cox J, Giguere P, Harris M, Hughes C, MacPherson P, O'Donnell S, Reimer J, Singh A, Barrett L, Bogoch I, Jollimore J, Lambert G, Lebouche B, Metz G, Rogers T, Shafran S; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.

CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494. No abstract available. Erratum in: CMAJ. 2018 Jun 25;190(25):E782.

11.

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.

Harris M, Ganase B, Watson B, Harrigan PR, Montaner JSG, Hull MW.

AIDS Res Ther. 2017 Nov 2;14(1):59. doi: 10.1186/s12981-017-0185-4.

12.

Antimicrobial stewardship for hospitalized patients with viral respiratory tract infections.

Lowe CF, Payne M, Puddicombe D, Mah A, Wong D, Kirkwood A, Hull MW, Leung V.

Am J Infect Control. 2017 Aug 1;45(8):872-875. doi: 10.1016/j.ajic.2017.03.025. Epub 2017 May 16.

PMID:
28526309
13.

Is there a rural/urban gap in the quality of HIV care for treatment-naïve HIV-positive individuals initiating antiretroviral therapy in British Columbia?

MacKenzie LJ, Hull MW, Samji H, Lima VD, Yip B, Zhang W, Lourenço L, Colley G, Hogg RS, Montaner JSG.

AIDS Care. 2017 Oct;29(10):1218-1226. doi: 10.1080/09540121.2017.1322678. Epub 2017 May 4.

PMID:
28472896
14.

Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.

Mah A, Hull MW, DeBeck K, Milloy MJ, Dobrer S, Nosova E, Wood E, Kerr T, Hayashi K.

Int J Drug Policy. 2017 Sep;47:137-143. doi: 10.1016/j.drugpo.2017.02.006. Epub 2017 Mar 24.

15.

Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study.

Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, Lima VD, Ahmed T, Kendall CE, Althoff KN, Justice AC, Barrios R, Shoveller J, Montaner JSG; Comparative Outcomes And Service Utilization Trends (COAST) study.

Lancet HIV. 2017 Jun;4(6):e270-e276. doi: 10.1016/S2352-3018(17)30029-2. Epub 2017 Mar 3.

16.

Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012.

Eyawo O, Franco-Villalobos C, Hull MW, Nohpal A, Samji H, Sereda P, Lima VD, Shoveller J, Moore D, Montaner JS, Hogg RS; Comparative Outcomes And Service Utilization Trends (COAST) study.

BMC Infect Dis. 2017 Feb 27;17(1):174. doi: 10.1186/s12879-017-2254-7.

17.

Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.

Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR.

HIV Clin Trials. 2017 Jan;18(1):39-47. doi: 10.1080/15284336.2016.1271503. Epub 2017 Jan 9.

PMID:
28067119
18.

Achieving the 90-90-90 target: incentives for HIV testing.

Wainberg MA, Hull MW, Girard PM, Montaner JSG.

Lancet Infect Dis. 2016 Nov;16(11):1215-1216. doi: 10.1016/S1473-3099(16)30383-8. No abstract available.

PMID:
27788971
19.

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.

Guillemi SA, Ling SH, Dahlby JS, Yip B, Zhang W, Hull MW, Lima VD, Hogg RS, Werb R, Montaner JS, Harris M.

J Int AIDS Soc. 2016 Sep 9;19(1):20995. doi: 10.7448/IAS.19.1.20995. eCollection 2016.

20.

Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.

Hull MW, Yoshida EM, Montaner JS.

Curr Infect Dis Rep. 2016 Jul;18(7):22. doi: 10.1007/s11908-016-0527-8. Review.

PMID:
27357277
21.

Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature.

Alshatti F, Moosavi S, Yoshida EM, Hull MW.

J Clin Virol. 2016 Jun;79:51-53. doi: 10.1016/j.jcv.2016.04.003. Epub 2016 Apr 11. Review.

PMID:
27105314
22.

Pre-exposure Prophylaxis Awareness Among Gay and Other Men who have Sex with Men in Vancouver, British Columbia, Canada.

Lachowsky NJ, Lin SY, Hull MW, Cui Z, Sereda P, Jollimore J, Rich A, Montaner JS, Roth EA, Hogg RS, Moore DM.

AIDS Behav. 2016 Jul;20(7):1408-22. doi: 10.1007/s10461-016-1319-8.

23.

Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: Opportunities for antimicrobial stewardship.

Havey TC, Hull MW, Romney MG, Leung V.

Am J Infect Control. 2015 Sep 1;43(9):946-50. doi: 10.1016/j.ajic.2015.05.020. Epub 2015 Jul 6.

PMID:
26159502
24.

Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada.

Wilmer A, Romney MG, Gustafson R, Sandhu J, Chu T, Ng C, Hoang L, Champagne S, Hull MW.

HIV Med. 2015 Mar;16(3):168-75. doi: 10.1111/hiv.12191.

25.

Time-dependence in mixture toxicity prediction.

Dawson DA, Allen EM, Allen JL, Baumann HJ, Bensinger HM, Genco N, Guinn D, Hull MW, Il'Giovine ZJ, Kaminski CM, Peyton JR, Schultz TW, Pöch G.

Toxicology. 2014 Dec 4;326:153-63. doi: 10.1016/j.tox.2014.10.015. Epub 2014 Nov 1.

26.

Trichodysplasia spinulosa: rare presentation of polyomavirus infection in immunocompromised patients.

Kirchhof MG, Shojania K, Hull MW, Crawford RI, Au S.

J Cutan Med Surg. 2014 Nov;18(6):430-5. Review.

PMID:
25348766
27.

HIV and liver transplantation: The British Columbia experience, 2004 to 2013.

Tan-Tam C, Liao P, Montaner JS, Hull MW, Scudamore CH, Erb SR, Yoshida EM.

Can J Infect Dis Med Microbiol. 2014 May;25(3):159-62.

28.

HIV treatment as prevention: the key to an AIDS-free generation.

Hull MW, Montaner JS.

J Food Drug Anal. 2013 Dec;21(4):S95-S101.

29.

Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years.

Lima VD, Sierra-Madero J, Wu Z, Singer J, Wood E, Hull MW, Richard Harrigan P, Montaner JS.

J Int AIDS Soc. 2014 May 6;17:18617. doi: 10.7448/IAS.17.1.18617. eCollection 2014.

30.

Reduction in community-onset methicillin-resistant Staphylococcus aureus rates in an urban Canadian hospital setting.

Wilmer A, Lloyd-Smith E, Romney MG, Champagne S, Wong T, Zhang W, Stenstrom R, Hull MW.

Epidemiol Infect. 2014 Mar;142(3):463-7. doi: 10.1017/S0950268813001568. Epub 2013 Jun 28.

PMID:
23809903
31.

Reply to Mandorfer et al.

Hull MW, Rollet K, Klein MB; Canadian Co-infection Cohort Investigators.

Clin Infect Dis. 2013 Mar;56(6):905-6. doi: 10.1093/cid/cis1036. Epub 2012 Dec 12. No abstract available.

PMID:
23243174
32.

Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention.

Hull MW, Wu Z, Montaner JS.

Curr Opin HIV AIDS. 2012 Nov;7(6):579-86. doi: 10.1097/COH.0b013e3283590617. Review.

PMID:
23076123
33.

Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients.

Hull MW, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, Saeed S, Klein MB; Canadian Co-infection Cohort Study Investigators.

AIDS. 2012 Sep 10;26(14):1789-94.

PMID:
22739388
34.

Water compatibility and organic transformations of organo-Zintl deltahedral clusters.

Hull MW, Sevov SC.

Chem Commun (Camb). 2012 Aug 11;48(62):7720-2. doi: 10.1039/c2cc32263c. Epub 2012 May 17.

PMID:
22595977
35.

Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.

Hull MW, Rollet K, Odueyungbo A, Saeed S, Potter M, Cox J, Cooper C, Gill J, Klein MB; Canadian Co-infection Cohort Investigators.

Clin Infect Dis. 2012 Jun;54(12):1798-805. doi: 10.1093/cid/cis289. Epub 2012 Mar 28.

PMID:
22460964
36.

Screening for methicillin-resistant Staphylococcus aureus (MRSA) in community-recruited injection drug users: are throat swabs necessary?

Lloyd-Smith E, Hull MW, Hawkins D, Champagne S, Kerr T, Romney MG.

Epidemiol Infect. 2012 Sep;140(9):1721-4. doi: 10.1017/S0950268811002421. Epub 2011 Dec 13.

PMID:
22152523
37.

Optimizing initial therapy for HIV infection.

Hull MW, Montaner JS.

J Infect Dis. 2011 Oct 15;204(8):1154-6. doi: 10.1093/infdis/jir506. No abstract available.

38.

Ritonavir-boosted protease inhibitors in HIV therapy.

Hull MW, Montaner JS.

Ann Med. 2011 Aug;43(5):375-88. doi: 10.3109/07853890.2011.572905. Epub 2011 Apr 18. Review.

PMID:
21501034
39.

Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy.

Hull MW, Montaner J.

Curr HIV/AIDS Rep. 2011 Jun;8(2):85-93. doi: 10.1007/s11904-011-0076-6. Review.

PMID:
21445551
41.

Community-associated methicillin-resistant Staphylococcus aureus is prevalent in wounds of community-based injection drug users.

Lloyd-Smith E, Hull MW, Tyndall MW, Zhang R, Wood E, Montaner JS, Kerr T, Romney MG.

Epidemiol Infect. 2010 May;138(5):713-20. doi: 10.1017/S0950268810000464. Epub 2010 Mar 5.

PMID:
20202284
42.

Epidemiology of treatment failure: a focus on recent trends.

Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS.

Curr Opin HIV AIDS. 2009 Nov;4(6):467-73. doi: 10.1097/COH.0b013e328331d353. Review.

PMID:
20048712
43.

Functionalization of nine-atom deltahedral Zintl ions with organic substituents: detailed studies of the reactions.

Hull MW, Sevov SC.

J Am Chem Soc. 2009 Jul 1;131(25):9026-37. doi: 10.1021/ja9025962.

PMID:
19496567
44.

Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.

Hull MW, Harris M, Lima V, Guillemi S, Harrigan PR, Montaner JS.

J Clin Pharmacol. 2009 Feb;49(2):155-61. doi: 10.1177/0091270008329550.

PMID:
19179294
45.

Changing global epidemiology of pulmonary manifestations of HIV/AIDS.

Hull MW, Phillips P, Montaner JSG.

Chest. 2008 Dec;134(6):1287-1298. doi: 10.1378/chest.08-0364. Review.

PMID:
19059959
46.

Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population.

Romney MG, Hull MW, Gustafson R, Sandhu J, Champagne S, Wong T, Nematallah A, Forsting S, Daly P.

Clin Infect Dis. 2008 Sep 15;47(6):768-74. doi: 10.1086/591128.

PMID:
18690803
47.

Organo-Zintl clusters soluble in conventional organic solvents: setting the stage for organo-Zintl cluster chemistry.

Hull MW, Sevov SC.

Inorg Chem. 2007 Dec 24;46(26):10953-5. Epub 2007 Nov 23.

PMID:
18034475
48.
49.

Indigenous microflora and innate immunity of the head and neck.

Hull MW, Chow AW.

Infect Dis Clin North Am. 2007 Jun;21(2):265-82, v. Review.

PMID:
17561071

Supplemental Content

Support Center